Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Tarih

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, MAY 29-31, 2020